Skip to content

Effect of Shexiang Baoxin Pill on long-term prognosis in Patients With STEMI

Effect of Shexiang Baoxin Pill on long-term prognosis in Patients With STEMI

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086572
Enrollment
Unknown
Registered
2024-07-05
Start date
2024-01-14
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-Element Myocardial Infarction

Interventions

Experimental group:Be given SBP immediately after admission as soon as possible + Conventional medicine and PPCI implemented as early as possible 12 h from the onset of the symptoms according to the g
Control group:Conventional medicine and PPCI implemented as early as possible 12 h from the onset of the symptoms according to the guidelines

Sponsors

Ordos Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age =18 years; 2. Chest pain <12 h; 3. The first electrocardiogram(ECG) showed ST segment elevation =0.1 mV in two or more adjacent leads.

Exclusion criteria

Exclusion criteria: 1. Advanced malignant tumor; 2. History of myocardial infarction; 3. Acute inflammatory or infectious disease; 4. Decompensated liver disease; 5. End-stage renal disease; 6. Severe heart failure (Killip III-IV); 7. History of coronary artery bypass; 8. Hypersensitivity to SBP; 9. Failure to complete the study and lack of follow-up.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;Blood glucose and lipid;Fasting blood glucose;Glycated hemoglobin level;Carotid plaque;Left ventricular end-diastolic diameter;Left atrial inner diameter;Left ventricular ejection fraction;Diastolic function measurement;The primary clinical endpoint events were major cardiovascular and cerebrovascular adverse events, including cardiac death, nonfatal reinfarction, new heart failure, transient ischemic attack, and new cerebral infarction.;Heart rate;Blood pressure;

Secondary

MeasureTime frame
Blood routine examination;Liver function;Blood uric acid;Homocysteine;Vitamin D levels;Carotid intima-media thickness;Left ventricular end-systolic diameter;Kidney function;

Countries

China

Contacts

Public ContactLiu Zhenbing

Ordos Central Hospital

LZHBL44@126.COM+86 136 2477 4699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026